Equities Analysts Set Expectations for C4 Therapeutics Q2 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Brookline Capital Management issued their Q2 2025 earnings per share (EPS) estimates for C4 Therapeutics in a report issued on Thursday, February 27th. Brookline Capital Management analyst L. Cann expects that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

A number of other brokerages also recently issued reports on CCCC. Stephens began coverage on C4 Therapeutics in a research report on Monday, November 18th. They set an “equal weight” rating and a $4.00 price objective for the company. Wells Fargo & Company upgraded shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $8.00 to $12.00 in a research report on Thursday, December 19th. Finally, UBS Group raised shares of C4 Therapeutics to a “hold” rating in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.50.

C4 Therapeutics Stock Performance

CCCC stock opened at $2.38 on Monday. C4 Therapeutics has a one year low of $2.21 and a one year high of $11.48. The firm has a market cap of $168.00 million, a PE ratio of -1.40 and a beta of 2.95. The firm’s 50 day moving average price is $3.46 and its 200-day moving average price is $4.74.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The company had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $4.43 million.

Hedge Funds Weigh In On C4 Therapeutics

Several institutional investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. boosted its stake in shares of C4 Therapeutics by 198.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,550,000 shares of the company’s stock valued at $5,580,000 after purchasing an additional 1,030,000 shares during the period. Point72 Asset Management L.P. boosted its position in C4 Therapeutics by 331.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,201,848 shares of the company’s stock valued at $6,851,000 after buying an additional 923,268 shares during the period. Wasatch Advisors LP grew its stake in shares of C4 Therapeutics by 17.1% in the third quarter. Wasatch Advisors LP now owns 5,677,368 shares of the company’s stock worth $32,361,000 after acquiring an additional 830,218 shares in the last quarter. Soleus Capital Management L.P. increased its position in shares of C4 Therapeutics by 5.7% during the fourth quarter. Soleus Capital Management L.P. now owns 6,978,942 shares of the company’s stock worth $25,124,000 after acquiring an additional 374,946 shares during the period. Finally, Millennium Management LLC raised its stake in shares of C4 Therapeutics by 1,548.3% in the fourth quarter. Millennium Management LLC now owns 360,125 shares of the company’s stock valued at $1,296,000 after acquiring an additional 338,277 shares in the last quarter. 78.81% of the stock is owned by institutional investors and hedge funds.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.